Preparing For Scale Up In The Early Phases Of Monoclonal Antibody Development

Monoclonal antibodies (mAbs) are a key part of the biopharmaceutical landscape. Although their manufacture is well established, the sensitive nature of biologic products continues to give rise to challenges. Efficient and reliable scale up is a key component of mAb production – and there are several considerations that need to be understood and reviewed early on in the process.

Explore scale up in the earlier phases of the product lifecycle with Kristina Pleitt from Thermo Fisher Scientific. Pleitt explains her role as Senior Manager in the Bioprocessing Collaboration Center, challenges during early scale up stages, and recommendations to save time and cost.